Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Operating Expenses: 2018-2024

Historic Operating Expenses for Allogene Therapeutics (ALLO) over the last 7 years, with Dec 2024 value amounting to $273.2 million.

  • Allogene Therapeutics' Operating Expenses fell 37.44% to $44.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $227.4 million, marking a year-over-year decrease of 23.66%. This contributed to the annual value of $273.2 million for FY2024, which is 16.66% down from last year.
  • As of FY2024, Allogene Therapeutics' Operating Expenses stood at $273.2 million, which was down 16.66% from $327.8 million recorded in FY2023.
  • Over the past 5 years, Allogene Therapeutics' Operating Expenses peaked at $335.7 million during FY2022, and registered a low of $258.2 million during FY2020.
  • Over the past 3 years, Allogene Therapeutics' median Operating Expenses value was $327.8 million (recorded in 2023), while the average stood at $312.2 million.
  • Per our database at Business Quant, Allogene Therapeutics' Operating Expenses grew by 27.84% in 2020 and then declined by 16.66% in 2024.
  • Yearly analysis of 5 years shows Allogene Therapeutics' Operating Expenses stood at $258.2 million in 2020, then climbed by 13.96% to $294.3 million in 2021, then climbed by 14.07% to $335.7 million in 2022, then fell by 2.34% to $327.8 million in 2023, then decreased by 16.66% to $273.2 million in 2024.